Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Heart Failure III: Clinical Manifestations

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinations.

Research square·2026

Same author

Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance.

Cell·2026

Same author

Outcomes of Lobectomy Versus Sublobar Resection for Clinical Stage IA3 Non-Small Cell Lung Cancer.

The Annals of thoracic surgery·2026

Same author

Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study.

Cancer letters·2026

Same author

Outcomes Of Neoadjuvant Chemoradiation Versus Neoadjuvant Chemotherapy For Esophageal Junction Signet Ring Cell Adenocarcinoma.

The Annals of thoracic surgery·2026

Same author

Outcomes of Thoracic Surgical Oncology Group 103: Multimodality management in risk-stratified patients with lung-limited metastatic colorectal cancer.

JTCVS open·2026

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Right heart sarcomas.

Ara Vaporciyan¹, Michael J Reardon

¹The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Methodist Debakey Cardiovascular Journal

|September 14, 2010

Summary

Primary cardiac sarcomas, particularly right heart sarcomas, require tailored treatment. Neoadjuvant chemotherapy followed by surgical resection shows promise for improving outcomes in these rare tumors.

Area of Science:

Cardiovascular Pathology
Surgical Oncology
Medical Oncology

Background:

Primary cardiac sarcomas are rare malignancies with prognosis significantly influenced by tumor location.
Right heart sarcomas often present with bulky, infiltrative growth and early metastasis.
Complete surgical resection is the primary goal for improving survival, but is often challenging.

Purpose of the Study:

To discuss the clinical experience with right heart sarcoma.
To evaluate a standardized treatment approach involving neoadjuvant chemotherapy and surgical resection.
To compare outcomes of standardized versus non-standardized treatment plans in right heart sarcoma.

Main Methods:

Review of clinical data for right heart sarcoma cases.

Related Experiment Videos

Last Updated: Jun 8, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Implementation of a neoadjuvant chemotherapy regimen prior to surgical resection.

Prospective IRB-approved clinical trial (ESPERO trial) to assess safety and efficacy of standardized treatment.

Main Results:

Right heart sarcoma prognosis without surgery is poor.
Complete surgical resection is the only modality shown to increase survival.
The ESPERO trial aims to improve the rate of microscopically complete resection from 33% and enhance patient survival.

Conclusions:

Right heart sarcoma necessitates a multimodal treatment strategy.
Neoadjuvant chemotherapy followed by surgical resection is a promising approach.
Standardized treatment protocols may improve resection rates and patient survival for right heart sarcoma.